Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab with SABR in metastatic tumors
2024-515678-29-00Phase 2Completed
- Sponsor
- Gustave Roussy
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab in metastatic colorectal adenocarcinoma (mCRC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC) and 1 more, sponsored by Gustave Roussy. Primary endpoint: One-year progression-free survival rate. Started Oct 2024; status: completed.
02
Drugs
atezolizumab
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)non-small cell lung cancer (NSCLC)renal cell carcinoma (RCC)Bone and soft tissue sarcoma
Beyond the preview
Go deeper on 2024-515678-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515678-29-00.